Boundless Bio

Recent Finacing

Series C

Recent Raise

$100M

Boundless Bio is a clinical-stage precision oncology company developing ecDNA-directed therapeutics and the ECHO diagnostic, using its Spyglass platform to discover synthetically lethal targets and advance BBI-355 Phase 1/2.

Founded 2018

California, United States

101-250

Publicly Traded

boundlessbio.com

Highlights

Focus Areas

Biotechnology

Health Care

Life Science

Oncology

Therapeutics

Recent Investors

Financials

$251.4M

Total Raised

3

Funding rounds

18

Investors

Team

Upgrade to view the team

See the team members at Boundless Bio.